Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas (BZKF-AYA)

University Hospital Regensburg

Status: Not yet enrolling

Conditions: Medulloblastoma; Embryonal Tumor; Glioma, Malignant; Ependymoma

Treatments: Diagnostic Test: Tissue, blood, cerebrospinal-spinal fluid

Study type: Observational

Funder types: Other

Identifiers

NCT06323408

BZKF-AYA_1.0

Details and patient eligibility

About

The treatment of adolescents and young adults (AYA, 15 to 39 years) with malignant intra-axial CNS parenchymal tumors such as IDH-mutated gliomas, medulloblastomas and ependymomas is still not curative in all cases. The tumor biology and clinical needs to diagnose and treat these tumors are comparable across all age groups, so an integrated treatment environment overseen by adult and pediatric neuro-oncology specialists seems promising to leverage synergisms and advance diagnostic and therapeutic development in these tumors. A comprehensive, prospective and integrated biomaterial and imaging-based pipeline for the multi-faceted evaluation of AYAs has not yet been established for AYA patients with brain tumors in Germany. Current diagnostic platforms neglect the integrative processing of data from MRI and FET-PET imaging, radiotherapy plans, tumor tissue, liquid biopsies and clinical data as well as prognostic markers. A prospective AYA pipeline can therefore enable a better understanding of the aforementioned high-risk CNS malignancies and promises clinical advances for AYA patients and the clinical and scientific research landscape.

Full description

Objectives: We are conducting a non-interventional study for AYAs with malignant intraaxial CNS parenchymal tumors. All 6 Bavarian BZKF sites are involved in the study. We will collect data on diagnostic and prognostic MRI and FET-PET imaging, quality assurance in radiotherapy and radiotherapy treatment patterns, diagnostic and predictive liquid biopsies from CSF and blood and targeted therapy approaches and integrate them bioinformatically with clinical data.

Work packages: WP01 Prediction of diagnosis by artificial intelligence (AI)-assisted processing of MRI and FET-PET; WP02 Analysis of response and relapse patterns by AI-assisted processing of MRI and FET-PET; WP03 Quality control of radiotherapy planning and patterns-of-care analysis; WP04 Prediction of response, relapse and treatment density using markers identified in liquid biopsies from CSF and blood; WP05 Identification of targets for targeted therapy from paraffin-embedded tissue (FFPE), CSF and blood; WP06 Investigation of clinical patterns and progression (PFS) or WP07 Bioinformatic integration of data to predict PFS, OS and patterns of response, relapse, treatment density and potential molecular targets.

Inclusion criteria: (1) first diagnosis of high-risk CNS tumors including IDHmutated gliomas, medulloblastomas, ependymomas, and other intra-axial primary brain tumors; (2) adolescents and young adults (AYA; 15 to 39 years); (3) Karnofsky status of 60 or higher; (4) multimodality therapy planned at the discretion of the medical professional; (5) expected survival min. 6 months; (6) informed consent by patient and (for patients under 18 years) legal representative; (7) complete material collection expected.

Exclusion criteria: (1) synchronous independent tumor disease, except basal cell carcinoma and carcinoma in situ; (2) participation in interventional clinical trial, except in standard arms of interventional clinical trials.

Enrollment: 72 estimated patients

Sex: All

Ages: 15 to 39 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. first diagnosis of high-risk CNS tumors including glioma IDHmutated, medulloblastoma, ependymoma and other intra-axial primary brain tumors
2. adolescents and young adults (AYA; 15 to 39 years)
3. Karnofsky status of 60 or higher
4. resection, extended biopsy or stereotactic biopsy with sufficient tissue volume
5. multimodal therapy planned at the discretion of the treating specialist
6. expected survival time of at least 6 months
7. informed consent from the patient or the patient's legal guardian prior to the first study procedure
8. complete material collection expected.

Exclusion criteria

1. synchronous independent tumor disease other than basal cell carcinoma and carcinoma in situ
2. participation in interventional clinical trial except in standard arms of interventional clinical trials.

Trial design

72 participants in 2 patient groups

Embryonal

Description:

Embryonal tumors, including medulloblastoma and ATRT

Treatment:

Diagnostic Test: Tissue, blood, cerebrospinal-spinal fluid

Glioma, IDH-mutated

Description:

IDH-mutated gliomas, including WHO grades 2, 3 and 4

Treatment:

Diagnostic Test: Tissue, blood, cerebrospinal-spinal fluid